ADAMTS13 Immune Complex Detection via Dual Binding Units
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting anti-ADAMTS13 antibodies in immune complexes are time-intensive, cumbersome, and lack sensitivity and accuracy, making it difficult to rapidly diagnose and treat conditions like acquired thrombotic thrombocytopenic purpura (TTP), where timely detection is crucial due to the disease's severity and potential for rapid progression to death.
Innovation Solution
A method involving a two-component binding mechanism using an ADAMTS13 binding unit and an antibody binding unit to specifically detect anti-ADAMTS13 antibodies complexed with ADAMTS13, allowing for the determination of both complexed and free antibodies, and ADAMTS13 activity, enhancing diagnostic accuracy and therapeutic monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell-based assays are used to detect immune complexes in serum samples, then detection capability is achieved, but the assay becomes time-intensive and cumbersome with low reproducibility
Solution Approach 1:
The invention extracts the detection of immune complexes from complex cell-based assays and implements it through a simplified two-component binding mechanism using ADAMTS13 binding unit and antibody binding unit, eliminating time-intensive cellular steps while maintaining detection capability
Solution Approach 2:
The invention replaces the mechanical cell-based assay system with a biochemical binding system using specifically designed binding units that recognize and capture immune complexes through molecular interactions, eliminating the need for cellular components and associated procedural complexity
2Measurement precision
If conventional assays are used to detect anti-ADAMTS13 antibodies, then detection is possible, but sensitivity and accuracy are insufficient for rapid diagnosis
Solution Approach 1:
The invention segments the detection process into two independent binding events: ADAMTS13 binding unit capturing the antigen-antibody complex and antibody binding unit detecting the antibody component, allowing each segment to be optimized for its specific function and enabling rapid parallel processing
Solution Approach 2:
The invention introduces ADAMTS13 binding unit and antibody binding unit as intermediary molecules that facilitate the detection process, enabling specific recognition and capture of immune complexes with high sensitivity while maintaining rapid assay performance
3Ease of operation
If simple assays are used to determine ADAMTS13 activity or total concentration, then ease of operation is improved, but limited use in diagnosing specific diseases like acquired TTP occurs
Solution Approach 1:
The invention creates a multi-functional assay system where the two-component binding mechanism can detect immune complexes, determine free antibody levels, and assess ADAMTS13 activity within a single platform, enabling broad diagnostic applicability while maintaining operational simplicity
Solution Approach 2:
The invention makes the assay dynamic and adaptable by using binding units that can detect different forms of ADAMTS13 (free, complexed, active, inactive) and antibody states, allowing the same basic methodology to be applied across various diagnostic scenarios including acquired TTP diagnosis and monitoring
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the sensitivity and accuracy of detecting anti-ADAMTS13 antibodies in immune complexes, enabling faster and more effective diagnosis and treatment of TTP by providing a rapid and reliable method for determining the ratio of free and complexed antibodies, which is critical for managing the disease.
Implementation Method 1
Target anti-ADAMTS13 antibodies are bound by ADAMTS13, or if already complexed to ADAMTS13, by an ADAMTS13 binding unit, which is an anti-ADAMTS13 antibody
Implementation Method 2
The antibodies are further bound by a moiety that recognizes the antibodies and /or their specific subclasses, termed the antibody binding unit, namely an anti-antibody antibody
Data Source
AI summary
The present invention relates to methods and means for detecting ADAMTS13 immune complexes in a sample. The methods include the steps of capturing and labelling immune complexes of anti-ADAMTS13 antibodies. Capturing and labelling may be achieved by two different binding units targeting the immune complexes. The invention further relates to diagnosing diseases associated with immunologic ADAMTS13 dysfunction like TTP (thrombotic thrombocy-topenic purpura).